低氧诱导因子脯氨酸羟化酶抑制剂治疗地中海贫血伴肾性贫血1例

Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of thalassemia with renal anemia:a case report

本文报告1例低氧诱导因子脯氨酸羟化酶抑制剂(hypoxiainducible factor prolyl hydroxylase inhibitor,HIFPHI)治疗地中海贫血合并肾性贫血的病例。患者为老年女性,患有β地中海贫血,突变基因CD41-42杂合,因高血压、糖尿病进展为尿毒症,并发肾性贫血。应用促红细胞生成素治疗后,患者贫血不能纠正,长期依赖输血,后改用HIF-PHI罗沙司他治疗有效。

We reported a case of hypoxia-inducible factor prolyl hydroxylase inhibitor(HIF-PHI)in the treatment of thalassemia combined with renal anemia.The patient was an elderly female withβ-thalassemia,heterozygous for the mutant gene CD41-42,and progressed to uremia due to hypertension and diabetes.After treatment with erythropoietin,the patient’s renal anemia could not be corrected,and she relied on blood transfusion for a long time.HIF-PHI Roxadustat is effective in treating this patient.